GlobeNewswire

Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
05/11/2026
New direct practice expense supply code supports more consistent valuation of CPT 0563T MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an [...]
VeonGen Announces FDA Alignment on Pivotal Phase 3 Development and Clinical Progress of VG801 for Stargardt Disease
05/11/2026
FDA alignment on pivotal Phase 3 study design and CMC strategy marks an important milestone in VG801’s clinical development VG801 demonstrates consistent and sustained functional improvements through Month 12 across [...]
Nova Anchora Announces $23 Million Financing to Advance Topical Collagen VII Therapy for Dystrophic Epidermolysis Bullosa
05/11/2026
Financing led by Viking Global Investors alongside a syndicate of venture philanthropy investors with deep expertise in epidermolysis bullosa Proceeds to support scale-up manufacturing, IND-enabling development of NvA- [...]
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
05/11/2026
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Incyclix Bio Establishes Steering Committee of Leading Breast Cancer Experts to Guide INX-315 Clinical Development
05/11/2026
Appointment of distinguished oncology leaders comes as Incyclix prepares for a potential pivotal trial in 2027 RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell [...]
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
05/11/2026
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU)
05/11/2026
Government-backed R&D program to advance next-generation LPU hardware and expand the LPU Lab platform Builds on LightSolver’s recent commercial and technical momentum, including the strategic partnership with Boeing [...]
Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the [...]
Annovis Announces Pricing of $21.0 Million Public Offering
05/11/2026
MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
05/11/2026
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7 [...]
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
05/11/2026
40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon lambda (IFNλ) exposure associated with greater antiviral and [...]
Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
05/11/2026
Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science Enterprises with support from Cancer Research Horizons and the University of Oxford, bringing together a world- [...]
ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
05/11/2026
CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of [...]
ArrayPatch boucle un tour de financement d’amorçage sursouscrit de 3,2 millions d’euros pour faire progresser ses traitements par micro-aiguilles de nouvelle génération
05/11/2026
CORK, Irlande, 05 nov. 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (« ArrayPatch »), une société de biotechnologie développant des traitements novateurs à base de micro-aiguilles, a annoncé aujourd’hui la clôture réussie de [...]
Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
05/11/2026
Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up [...]
CurePSP Names First Recipients of Biomarker Accelerator Program, Awarding Its Largest Research Grants to Date
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CurePSP has awarded more than $1.4 million through its Biomarker Accelerator Program to three researchers working to find reliable biomarkers for progressive supranuclear [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026 , Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Resalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss Signals
05/11/2026
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 The Phase 1b study in healthy overweight and moderately obese [...]
Interim Report Q3 2026: Successful product launches leading to 2% organic revenue growth and margin expansion
05/11/2026
Highlights The Enterprise division delivered organic revenue growth of 1%, following positive market reception of the second wave of the Evolve3 launch. The development reflects continued solid performance in North [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum